Abstract: Disclosed herein is an ophthalmic formulation comprising a compound of formula (I): wherein R1 is a linear or branched C9-C33 alkyl or a linear or branched C9-C33 alkenyl with 1 to 4 double bonds; R2 is a linear or branched C9-C19 alkyl or a linear or branched C9-C19 alkenyl with 1 to 4 double bonds; and an ophthalmologically acceptable carrier.
Abstract: Methods for the treatment of stroke, such as stroke of undetermined origin, by administration of xenon (Xe)-loaded liposome compositions are provided. In some aspects, Xe is encapsulated in echogenic liposomes and release of Xe can be enhanced by application of ultrasound stimulation. Compositions for use in treating stroke, such as liposomes loaded with Xe or Xe in combination with H2 or H2S, are also provided.
Type:
Grant
Filed:
August 9, 2013
Date of Patent:
August 6, 2019
Assignee:
THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM
Inventors:
Shao-Ling Huang, Melvin E. Klegerman, Yong-Jian Geng, Hyunggun Kim, David D. McPherson
Abstract: Compositions and methods for the treatment of drug-induced long QT syndrome and other cardiac channelopathies are disclosed herein. The compositions and methods of the present invention comprise binding one or more QT prolonging drugs with a liposome prior to parenteral (intravenous or subcutaneous) administration, or administration of an empty liposome prior to or concomitantly with therapeutic agents known to have a high risk of QT prolongation, or immediately following an envenomation. The results presented show an abrogation of the adverse effects of QT prolonging drugs in a dose-dependent manner by the compositions of the present invention.
Abstract: The present invention provides liposome compositions containing substituted ammonium and/or polyanion, and optionally with a desired therapeutic or imaging entity. The present invention also provide methods of making the liposome compositions provided by the present invention.
Type:
Grant
Filed:
November 29, 2016
Date of Patent:
July 16, 2019
Assignee:
Ipsen Biopharm Ltd.
Inventors:
Keelung Hong, Daryl C. Drummond, Dmitri Kirpotin
Abstract: Compositions and methods are provided for preventing one or more cardiac channelopathies or conditions resulting from irregularities or alterations in cardiac patterns, or both, in a human or animal subject comprising: one or more pharmacologically active agents that causes at least one of IKr channel inhibition or QT prolongation by inhibiting the activity of an ether-a-go-go-related gene (hERG); and one or more liposomes, wherein the liposomes are empty liposomes and administered prior to, concomitantly, or after administration of the pharmacologically active agent.
Type:
Grant
Filed:
January 11, 2017
Date of Patent:
July 16, 2019
Assignee:
Sighpath Pharma Inc.
Inventors:
Lawrence Helson, George M. Shopp, Annie Bouchard
Abstract: Provided are a cationic lipid which facilitates the introduction of a nucleic acid into, for example, a cell or the like; a composition containing the cationic lipid and a nucleic acid; a method for introducing a nucleic acid into a cell by using a composition containing the cationic lipid and the nucleic acid; and the like. The cationic lipid is, for example, a cationic lipid represented by formula (A): formula (A): (wherein R1 is alkenyl or the like, R2 is alkenyl or the like, R3 and R4 are each alkyl, or are combined together to form alkylene, or R3 and R5 are combined together to form alkylene, R5 is a hydrogen atom or the like, or is combined together with R3 to form alkylene, X1 is alkylene, and X2 is a single bond or alkylene).
Abstract: In accordance with the purpose(s) of the present disclosure, as embodied and broadly described herein, embodiments of the present disclosure, in one aspect, relate to nanoparticles, compositions including nanoparticles, methods of making nanoparticles, and the like. In particular, embodiments of the present disclosure include nanoparticles and compositions for the sustained release (e.g., release at a predetermined rate to maintain a certain concentration for a certain period of time) of an agent, such as a small interfering RNA (siRNA) from the nanoparticle.
Type:
Grant
Filed:
March 13, 2013
Date of Patent:
June 18, 2019
Assignee:
The Board of Trustees of the Leland Stanford Junior University
Inventors:
Tatsiana Lobovkina, Gunilla B. Jacobson, Richard N. Zare, Evgenios Neofytou, Ramin E. Beygui, Marie Russo
Abstract: This disclosure provides generally for antimicrobial compositions and methods of use comprising an anthocyanin, an anthocyanidin or metabolites thereof. Methods for promoting healing of a wound using these compositions are also disclosed. These compositions have broad spectrum antimicrobial activity and are safe for human and animal uses. Further, these compositions are safe for medical uses and industrial uses as antiseptic preparations to reduce or prevent microbial growth.
Abstract: This disclosure provides generally for antimicrobial compositions and methods of use comprising an anthocyanin, an anthocyanidin or metabolites thereof. Methods for promoting healing of a wound using these compositions are also disclosed. These compositions have broad spectrum antimicrobial activity and are safe for human and animal uses. Further, these compositions are safe for medical uses and industrial uses as antiseptic preparations to reduce or prevent microbial growth, including killing bacterial biofilms.
Abstract: The present document describes a compressible delivery formulation for transmucosal delivery of at least one compound which includes a micronized powder base; and a desiccated liposome formulation comprising at least one liposome containing at least one compound, process of making the same and process for making dosage forms from the formulation.
Abstract: The present invention relates to a process for producing capsules comprising a composition comprising coffee oil. The invention also relates to capsules obtainable by such process. In addition the invention relates to compositions, food ingredients and food products comprising such capsules.
Type:
Grant
Filed:
May 12, 2014
Date of Patent:
January 15, 2019
Assignee:
Nestec S.A.
Inventors:
Ana Luiza Braga, Zeynel Deniz Gunes, Joeska Husny, Daniel Andre Pretre, Elodie Soussan
Abstract: Topical compositions containing lysate of human parthenogenetic stem cells (hpSCs), preferably within a liposomal dispersion, that reduce the visible signs of skin aging and/or cellulite.
Type:
Grant
Filed:
August 2, 2011
Date of Patent:
January 8, 2019
Inventors:
Andrey Semechkin, Nikolay A. Turovets, Larisa S. Agapova, Russell A. Kern, Jeffrey D. Janus
Abstract: A method for isolation of exosomes from bovine colostrum powder or goat colostrum powder, and the use of the isolated exosomes as nano carriers for small drug molecules, is described. Exosomes isolated from bovine colostrum powder averaged <85 nm in size, carried the surface-bound protein markers, Alix, TSG101, CD63 and CD81, and accepted various lipophilic (curcumin, withaferin A, paclitaxel) and hydrophilic (anthocyanidins) agents to serve as a nano carrier.
Abstract: A method of inhibiting the release of a proinflammatory cytokine in a cell is disclosed. The method comprises treating the cell with a cholinergic agonist. The method is useful in patients at risk for, or suffering from, a condition mediated by an inflammatory cytokine cascade, for example endotoxic shock. The cholinergic agonist treatment can be effected by stimulation of an efferent vagus nerve fiber, or the entire vagus nerve.
Type:
Grant
Filed:
December 12, 2014
Date of Patent:
January 1, 2019
Assignee:
The Feinstein Institute for Medical Research
Abstract: The present invention includes methods and compositions to enhance, inter alia, wound repair by administration of 2,3-biphosphoglycerate, myo-inositol trispyrophosphate, or a functional variant thereof.
Abstract: A method for treating a glycoprotein-related disease is disclosed, which comprises: administering a first effective amount of phenol red and a second effective amount of an organic arsenic compound to a subject in need thereof.
Abstract: What is described is a method for preparing a liposome that efficiently encapsulates a negatively charged therapeutic polymer, e.g., siRNA. The process involves preparing a lipid mixture comprising a cationic lipid in a water miscible organic solvent, such as ethanol, at a concentration of 2.3 mg/ml, and adding this solution to the polymer dissolved in water to a final concentration of 35% ethanol in water. The final charge ratio of drug:lipid is 1:2.5. The resulting nanoparticles have a mean size of 50 to 150 nm.
Type:
Grant
Filed:
February 10, 2017
Date of Patent:
December 18, 2018
Assignee:
Nitto Denko Corporation
Inventors:
Victor Knopov, Richard P. Witte, Priya Karmali, Robin Lee, David Webb, Violetta Akopian
Abstract: This disclosure provides generally for antimicrobial compositions and methods of use comprising an anthocyanin, an anthocyanidin or metabolites thereof. Methods for promoting healing of a wound using these compositions are also disclosed. These compositions have broad spectrum antimicrobial activity and are safe for human and animal uses. Further, these compositions are safe for medical uses and industrial uses as antiseptic preparations to reduce or prevent microbial growth, including killing bacterial biofilms.
Abstract: The disclosure describes a composition comprising a lipidaceous carrier and a peptide complex formed from poly-L-lysine or a salt thereof; and either poly-L-glutamic acid or poly-L-aspartic acid, or a salt thereof. The composition can be used to prevent or treat a disease related to pulmonary surfactant dysfunction, such as hyaline membrane disease (HMD), respiratory distress syndrome (RDS), hydrocarbon poisoning, near-drowning, HIV/AIDS-related lung diseases, adult respiratory distress syndrome (ARDS) or acute lung injury (ALI), asthma, tuberculosis (TB) or severe acute respiratory syndrome (SARS). Alternatively, the composition can be used to increase the permeability of a pharmaceutical compound or composition across a membrane of a subject or to act as a carrier. The poly-L-lysine or salt thereof is longer than the poly-L-glutamic acid or poly-L-aspartic acid so that the complex that forms has a charge-neutralized region and a positively-charged region.
Type:
Grant
Filed:
February 25, 2011
Date of Patent:
November 13, 2018
Assignee:
Stellenbosch University
Inventors:
Johann Martin Van Zyl, Johan Smith, Arthur Owen Hawtrey, Pieter Van Der Bijl